Immunicum has announced that Sven Rohmann has been appointed Chief Executive Officer (CEO) effective immediately.
Bringing 30 years of industry experience from biotechnology and pharmaceutical companies as well as life science investment and company sale and acquisition experience, Rohmann will be leading Immunicum as it continues to develop ilixadencel, the company’s cell-based, off-the-shelf immune primer, and other programs for the treatment of solid tumor, it states.
“Sven has an impressive track record of creating value and as a deal maker. He brings a wealth of experience in leading successful biotechnology companies and bringing innovative new medicines all the way through development to product launch,” says Michael Oredsson, Chairman of Immunicum’s Board of Directors. “I am confident that Immunicum will benefit from his vast knowledge of the global biopharmaceutical industry, his strong network and his demonstrated transformative management expertise. We also want to express our gratitude to Alex Karlsson-Parra, who has navigated Immunicum through an important period as the interim CEO, and can now return to his core function as Chief Scientific Officer.”
More than three decades of executive experience
Rohmann brings more than three decades of experience as a successful executive in the industry, most recently as acting CEO for Oasmia Pharmaceuticals, a Swedish publicly-listed, commercial-stage oncology company. At Oasmia Pharmaceuticals he raised SEK 400 million to launch Apealea, leading to its subsequent out-licensing for up to $678 million. Earlier in his career, Rohmann was the founding CEO at Ganymed Pharmaceuticals, where he advanced its lead program from discovery towards clinical Phase II, leading to the acquisition by Astellas. He also held the CEO position at BioVision where he successfully transformed its business resulting in its acquisition by Digilab Inc. Rohman has extensive big pharma experience from his senior managerial positions at Novartis and Merck KGaA. During his 10-year tenure at Merck KGaA, he built an oncology-focused product portfolio that included the launch of Erbitux, generating over $2 billion in revenues.
Rohmann received his medical degree from the University of Mainz, Germany; his Ph.D. in medicine from the Erasmus University in Rotterdam, the Netherlands; and an Executive MBA from the Kellogg School of Management in the USA.
